CLINICAL TRIAL

Barley for Healthy Subjects (HS)

Waitlist Available · 18 - 65 · Male · Toronto, Canada

Metabolic Availability of Lysine From Barley in Young Adult Men

See full description

About the trial for Healthy Subjects (HS)

Treatment Groups

This trial involves 2 different treatments. Barley is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Barley
DIETARYSUPPLEMENT
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.

Eligibility

This trial is for male patients between 18 and 65 years old. There are 3 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Not on any medications that could affect protein or amino acid metabolism e.g. steroids.
Male, age 18 - 40 years, Healthy with no known clinical condition which would affect protein or AA metabolism, ex. Diabetes
Stable Body Weight (±0 to 5lb weight gain or loss in the last 3 months)
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 8 hrs
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 8 hrs.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Barley will improve 1 primary outcome in patients with Healthy Subjects (HS). Measurement will happen over the course of 8 hrs.

Phenylalanine Oxidation
8 HRS
Breath samples will be collected from each subject on each study day and the 13C enrichment measured by mass spectrometry. This will be plotted against phenylalanine intake in the reference and barley diets to determine the amount of lysine available in barley.

Who is running the study

Principal Investigator
G. C.
Glenda Courtney-Martin, Dietitian
The Hospital for Sick Children

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Have there been other clinical trials involving barley?

There is a growing interest in barley as a food supplement among the elderly and in those with certain metabolic disorders. Nevertheless, there are insufficient clinical trials to conclude that barley has beneficial or toxic effects. The current evidence is limited mainly by small sample sizes.

Anonymous Patient Answer

What causes healthy subjects (hs)?

A variety of triggers or conditions are possible, including hormones, chemical contaminants, infection, and other non-biological events. No single explanation or cause could explain most of the associations, but our study confirms that exposure to multiple environmental risk factors is common for hs and that hs could have different causal pathways for hs and LOA.

Anonymous Patient Answer

What is healthy subjects (hs)?

Healthy subjects were defined as subjects having no self-reported medical, psychiatric or substance use disorders, using standardized self-report validated tests and validated peer-review criteria. The group of healthy subjects used includes the general population.

Anonymous Patient Answer

Can healthy subjects (hs) be cured?

The study suggests that there are no significant changes between baseline and follow-up in the different H-P tests in a sample of healthy subjects matched with the patients, and therefore, H-P test cannot be regarded as a treatment for curing.

Anonymous Patient Answer

What are common treatments for healthy subjects (hs)?

There are significant differences in the treatments taken by healthy subjects and patients with prostate cancer. This has an effect on overall outcomes, but it is unclear whether patients with prostate cancer are at a greater risk of complications as a result of differences in the treatment that they are receiving compared to that recommended for the hs. Further studies are needed to inform treatment decisions.

Anonymous Patient Answer

How many people get healthy subjects (hs) a year in the United States?

Around 20 million US adults have a hs in a given year. This makes up 32.3% of the US adult population. For the elderly, the hs and hs' percentages are higher.

Anonymous Patient Answer

What are the signs of healthy subjects (hs)?

The changes that have been reported in some studies could be a result of the difference in the psychopathology of the subjects analyzed and not a result of the use of hs as a control group.

Anonymous Patient Answer

What is the latest research for healthy subjects (hs)?

The authors state that the latest research for health subjects is that HSPs are more likely to be screened (by population-based screening programs), that healthier individuals have a better prognosis, and that HSPs with screening are able to be more accurately evaluated and categorized. The authors also note that because more HSPs are screened for HCC than are HCs, HCs may be at higher risk for HCC.

Anonymous Patient Answer

What are the latest developments in barley for therapeutic use?

Barley has been shown to have a multifaceted antioxidant response to a pathogen-by-pathogen interaction assay and a significant antimicrobial effect against a Gram-positive and Gram-negative bacterial pathogen. Other in vivo studies showed anti-inflammatory effects when barley was grown as fodder for beef cattle.

Anonymous Patient Answer

Who should consider clinical trials for healthy subjects (hs)?

Despite their important role, clinical trials in the hs cohort may become increasingly underused due to the relatively high cost and/or rarity of most diseases of interest in hs. We discuss possible reasons for this and ways in which it can be improved.

Anonymous Patient Answer

What is the primary cause of healthy subjects (hs)?

Hs are not necessarily as healthy as we would expect. We found evidence that certain genes play a role in the immune system of hs. HLA alleles in hs should be taken into consideration when evaluating genetic differences in hs. The gene polymorphisms evaluated in the present study may be further investigated in order to develop biomarkers for further investigation.

Anonymous Patient Answer

How serious can healthy subjects (hs) be?

For many of the tests, subjects could be considered as having an effect on test performance when compared to a control group. Subjects who scored above the average in several test sections were more likely to exhibit poorer performance than other subjects and were likely to have low IQ when compared to subjects who scored below the average in multiple sections. Subjects (hs) who scored above the group average in the same subject sections were more likely to perform similarly as subjects (hs) who scored above the average in different sections of the same test than subjects (hs) who scored below the average in the same or different sections.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Healthy Subjects (HS) by sharing your contact details with the study coordinator.